The human body is comprised of a large collection of diverse cell types, each providing a specialized and context-specific function. The establishment and maintenance of a cell's identity is largely driven by chromatin structure. Novel genomic tools, such as ATAC-seq, enable highly multiplexed readout of regulatory and functional elements in the genome; however, these approaches only infer the chromatin structure and regulation but do not capture how the structural architecture of the genome is related to regulation and function. Here, we propose to leverage the existing expertise between the Chen and Buenrostro labs by combining fluorescent in situ sequencing, super-resolution microscopy, and ATAC-seq to develop and validate in situ ATAC-seq and ATAC-ExSeq, novel technologies that directly sequence genomic regulatory elements within the context of the 3D architecture of the genome. Our approach will involve the development of molecular biology protocols in conjunction with complementary hardware and software platforms. We will utilize these technologies to characterize the structural organization of the epigenome as well as explore multi-modal in situ assays for transcription factor binding and RNA co-localization. These in situ technologies will represent a fundamentally new and enabling capability for studying chromatin architecture and single-cell epigenomics.

Public Health Relevance

Current methods used to study the epigenome, the structure and modifications of DNA that regulate our genes, lack the ability to link spatial context of the epigenome with regulatory the development and role of cells in health and disease. This proposal aims to develop ATAC-ExSeq, a novel technology that has the ability to directly sequence genomic regulatory elements within the context of the 3D architecture of the genome, to gain insights into the fundamental biology of how the genome is regulated and organized. These novel tools will allow us to probe and develop hypotheses of how changes in the epigenome lead to specific changes in normal and disease cell types, which can help guide the direction of therapeutics that intervene in disease progression. elements that define

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21HG009749-02
Application #
9547481
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Pazin, Michael J
Project Start
2017-08-18
Project End
2019-05-31
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Broad Institute, Inc.
Department
Type
DUNS #
623544785
City
Cambridge
State
MA
Country
United States
Zip Code